食道癌藥物市場：依治療類型、適應症、通路和地區分類。

預計到 2026 年，食道癌治療市場規模將達到 47.8 億美元，到 2033 年將達到 67.8 億美元。預計從 2026 年到 2033 年，該市場將以 6.7% 的複合年成長率成長。

食道癌起源於食道內壁細胞。主要症狀包括吞嚥困難（吞嚥障礙）、體重無故下降、胸痛、消化不良或灼熱感、咳嗽和聲音沙啞。多西他賽、離胺酸和鹽酸替吡嘧啶等藥物已獲得美國食品藥物管理局（FDA）核准，是治療食道癌的常用化療藥物。免疫治療藥物Pembrolizumab單抗也用於治療食道癌。 2017年，FDA核准Pembrolizumab（Keytruda）用於治療進行性局部或轉移性胃癌，或胃食道交界處腺癌。

市場動態

全球食道癌發生率的不斷上升預計將推動食道癌治療市場的成長。根據世界癌症研究基金會（WCRF）2018年發布的報告，食道癌是男性第七大常見癌症，女性第十三大常見癌症。 2018年，全球報告的新增病例超過50萬例。此外，老年人罹患食道癌的風險更高，男性也更容易罹患此病。例如，美國臨床腫瘤學會（ASCO）2018年發布的數據顯示，45至70歲族群罹患食道癌的風險最高。

然而，目前尚無藥物療法能夠徹底治癒食道癌，食道癌患者的存活率在治療開始五年後顯著下降。預計食道癌藥物在治療開始五年後將不再有效，這將阻礙食道癌藥物市場的成長。例如，根據2019年1月在ASCO會議上發表的一項研究，食道癌患者的五年存活率為19%。

本次調查的主要特點。

• 本報告對食道癌治療市場、市場規模以及 2026 年至 2033 年預測期內的複合年成長率 (%) 進行了詳細分析，其中 2025 年為基準年。
• 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數對全球食道癌治療市場的主要企業進行了分析：公司概況、財務表現、產品系列、企業發展區域、分銷策略、主要發展和策略。
• 透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、政府主導的舉措、技術升級、市場擴張和行銷策略做出明智的決策。
• 本報告面向該行業的眾多相關人員，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • PEST分析
  • 波特五力分析
  • 市場機遇
  • 法規環境
  • 主要進展
  • 產業趨勢

第4章 全球食道癌治療市場：依治療類型分類，2026-2033年

• 化療
• 多西他賽
• Irinotecan
• 離胺酸和奇皮拉西
• Carboplatin和紫杉醇
• Cisplatin和5-Fluorouracil
• Cisplatin和Capecitabine
• 分子標靶治療
• 曲妥珠單抗
• Ramucirumab
• 免疫療法（Pembrolizumab）

第5章 全球食道癌治療市場：依適應症分類，2026-2033年

• 腺癌
• 胃腸道基質腫瘤
• 類癌腫瘤
• 鱗狀細胞癌
• 其他

第6章 全球食道癌治療市場：依通路分類，2026-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球食道癌治療市場：依地區分類，2026-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第8章 競爭情勢

• 熱圖分析
• 市佔率分析（3x3矩陣）
• 公司簡介
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Johnson &Johnson
  • Gilead Sciences
  • Genentech, Inc.
  • Sanofi-Aventis
  • Merck &Co

第9章 分析師建議

• 機會
• 分析師意見
• Coherent Opportunity Map

第10章

• 參考
• 調查方法

Esophageal Cancer Drugs Market is estimated to be valued at USD 4.78 Bn in 2026 and is expected to reach USD 6.78 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.

Market Dynamics

Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.

However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.

Key features of the study

• This report provides in-depth analysis of the esophageal cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global esophageal cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• By Therapy Type
  • Chemotherapy
  • Docetaxel
  • Irinotecan
  • Trifluridine
  • Tipiracil
  • Carboplatin and Paclitaxel
  • Cisplatin
  • 5-fluorouracil
  • Cisplatin with Capecitabine
  • Targeted Drug Therapy
  • Trastuzumab
  • Ramucirumab
  • Immunotherapy (Pembrolizumab)
• By Disease Indication
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Squamous Cell Carcinoma
  • Others
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Amgen Inc.
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences
  • Genentech, Inc.
  • Sanofi-Aventis
  • Merck & Co.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Therapy Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • PEST Analysis
  • PORTER's Five Forces Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global Esophageal Cancer Drugs Market, By Therapy Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Chemotherapy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Docetaxel
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Irinotecan
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Trifluridine and Tipiraci
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Carboplatin and Paclitaxel
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Cisplatin and 5-fluorouracil
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Cisplatin with Capecitabine
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Targeted Drug Therapy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Trastuzumab
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Ramucirumab
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Immunotherapy (Pembrolizumab)
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adenocarcinomas
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Gastrointestinal Stromal Tumors
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Carcinoid Tumors
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Squamous Cell Carcinoma
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Esophageal Cancer Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Online Pharmacy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Esophageal Cancer Drugs Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis (3x3 Matrix)
• Company Profiles
  • Amgen Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Eli Lilly and Company
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • F. Hoffmann-La Roche
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Bristol-Myers Squibb Company
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Bristol-Myers Squibb
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Novartis AG
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Johnson & Johnson
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Gilead Sciences
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Genentech, Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Sanofi-Aventis
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Merck & Co
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. Section

• References
• Research Methodology
• About Us and Sales Contact